Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

U.S. Stem Cell Inc (USRM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,864
  • Shares Outstanding, K 375,080
  • Annual Sales, $ 5,520 K
  • Annual Income, $ -3,480 K
  • 36-Month Beta 6.26
  • Price/Sales 1.24
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/14/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0160 +10.00%
on 12/14/18
0.0245 -28.16%
on 11/19/18
-0.0044 (-20.00%)
since 11/14/18
3-Month
0.0160 +10.00%
on 12/14/18
0.0400 -56.00%
on 10/05/18
-0.0062 (-26.05%)
since 09/14/18
52-Week
0.0160 +10.00%
on 12/14/18
0.0880 -80.00%
on 04/09/18
-0.0184 (-51.11%)
since 12/14/17

Most Recent Stories

More News
Dr. Kristin Comella Featured on Robert Scott Bell Show

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0176 (-3.83%)
USRM Posts 25% Nine Month Revenue Increase From 3Q 2017

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced third quarter results for this...

USRM : 0.0176 (-3.83%)
USRM Posts 25% Nine Month Revenue Increase From 3Q 2017

SUNRISE, Fla. , Nov. 7, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0176 (-3.83%)
Adipose Stem Cells Demonstrate Effectiveness in Repairing Decubitus Ulcers

SUNRISE, Fla. , Oct. 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0176 (-3.83%)
USRM Chief Science Officer Featured on YourVoice™ America

SUNRISE, Fla. , Oct. 1, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0176 (-3.83%)
USRM Chief Science Officer Featured on YourVoice(TM) America

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0176 (-3.83%)
Dr. Kristin Comella Joins Top Docs in Fix for Female Hormones Seminar

SUNRISE, Fla. , Sept. 26, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0176 (-3.83%)
Dr. Kristin Comella Joins Top Docs in Fix for Female Hormones Seminar

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0176 (-3.83%)
USRM Hires Senior VP of US & International Sales

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Phil Posa has joined its executive...

USRM : 0.0176 (-3.83%)
World Bodybuilding Expert Interviews USRM Chief Science Officer At Paleo F(X) Conference

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the release of USRM Chief Science...

USRM : 0.0176 (-3.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade USRM with:

Key Turning Points

2nd Resistance Point 0.0207
1st Resistance Point 0.0191
Last Price 0.0176
1st Support Level 0.0160
2nd Support Level 0.0145

See More

52-Week High 0.0880
Fibonacci 61.8% 0.0605
Fibonacci 50% 0.0520
Fibonacci 38.2% 0.0435
Last Price 0.0176
52-Week Low 0.0160

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar